VYNE Therapeutics (VYNE) Cash from Operations (QoQ) (2017 - 2025)
VYNE Therapeutics (VYNE) Cash from Operations (QoQ) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 5.43% |
| Mar 31, 2025 | -27.36% |
| Dec 31, 2024 | -5.75% |
| Sep 30, 2024 | -0.33% |
| Jun 30, 2024 | -6.28% |
| Mar 31, 2024 | -55.36% |
| Dec 31, 2023 | 0.29% |
| Sep 30, 2023 | 46.19% |
| Jun 30, 2023 | -74.77% |
| Mar 31, 2023 | -13.86% |
| Dec 31, 2022 | 32.48% |
| Sep 30, 2022 | 13.37% |
| Jun 30, 2022 | 9.01% |
| Mar 31, 2022 | 9.77% |
| Dec 31, 2021 | 42.89% |
| Sep 30, 2021 | -7.90% |
| Jun 30, 2021 | -29.53% |
| Mar 31, 2021 | 50.54% |
| Dec 31, 2020 | -7.35% |
| Sep 30, 2020 | 34.08% |